Prenatal tobacco prevention and cessation interventions for women in low- and middle-income countries
- PMID: 20235895
- PMCID: PMC3918940
- DOI: 10.3109/00016341003678450
Prenatal tobacco prevention and cessation interventions for women in low- and middle-income countries
Abstract
Although the prevalence of tobacco use is decreasing in many high-income countries, it is increasing in many low- and middle-income countries. The health and economic burden of increasing tobacco use and dependence is predictable and will have devastating effects in countries with limited resources, particularly for vulnerable populations such as pregnant women. We sought to review effective tobacco prevention and intervention strategies for decreasing tobacco use and secondhand smoke exposure before and during pregnancy in high-, middle-, and low-income countries. We reviewed several types of interventions, including population-level efforts (increasing tobacco prices, implementing tobacco control policies), community interventions, clinical interventions, and pharmacological treatments. A second purpose of this report is to present findings of an international expert working group that was convened to review the evidence and to establish research priorities in the following areas: (a) preventing the uptake and reducing tobacco use among girls and women of reproductive age; and (b) reducing tobacco use and secondhand smoke exposure among pregnant women. The working group considered the evidence on existing interventions in terms of burden of disease, intervention impact, intervention costs, feasibility of integration into existing services, uniqueness of the contribution, and overall feasibility. Finally, we present the working group's recommendations for intervention research priorities.
Conflict of interest statement
Dr. Oncken has received honoraria from Pfizer (New York, NY). She has received at no cost nicotine and/or placebo products from Glaxo-SmithKline (Philadelphia, PA) and from Pharmacia & Upjohn (Helsingborg, Sweden) for research studies. She has received research grant funding from Pfizer and from Nabi Biopharmaceuticals (Boca Raton, FL). Dr. Samet was previously a member of the Pfizer Global Tobacco Advisory Board. Dr. Bloch has provided depositions on behalf of the U.S. government in the U.S. Department of Justice lawsuit, U.S.A. v. Philip Morris USA, Inc. et al., as part of her official duties. Belizan, Berghella, Dietz, Lando, Tolosa, and Tong report no conflicts of interest.
Figures
References
-
- World Health Organization. Report on the global tobacco epidemic: the MPOWER package. Geneva: World Health Organization; 2008.
-
- Warren CW, Jones NR, Peruga A, Chauvin J, Baptiste JP, Costa de Silva V, et al. Global youth tobacco surveillance, 2000–2007. MMWR Surveill Summ. 2008;57(1):1–28. - PubMed
-
- Centers for Disease Control and Prevention. The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services; 2004. - PubMed
-
- Gupta PC, Subramoney S. Smokeless tobacco use and risk of stillbirth: a cohort study in Mumbai, India. Epidemiology. 2006;17(1):47–51. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
